Literature DB >> 1317477

Effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease.

M L Watson1, A M Macnicol, P L Allan, A F Wright.   

Abstract

The pathogenesis of hypertension in autosomal-dominant polycystic kidney disease (ADPKD) is unclear, but increased activity of the renin-angiotension system may contribute. The renal and systemic hemodynamic response to lisinopril, an angiotension converting enzyme (ACE) inhibitor, in patients with ADPKD without renal failure was compared with the response in matched unaffected family members. Mean blood pressure and renal vascular resistance decreased in the affected group after lisinopril, with no significant change in the unaffected group. Glomerular filtration rate (GFR) was unchanged and therefore filtration fraction fell significantly. Changes in urinary excretion of 6-keto-PGF1 alpha and kallikrein suggested that increased renal synthesis of PGI2 or activation of the renal kallikrein-kinin system were not likely to be responsible for the hemodynamic effects. The acute decrease in renal vascular resistance without change in GFR suggests that ACE inhibition may have a particular value in the treatment of hypertension associated with ADPKD which should be assessed by further long-term studies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317477     DOI: 10.1038/ki.1992.28

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

Review 1.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD).

Authors:  Anna S Nikonova; Alexander Y Deneka; Anna A Kiseleva; Vladislav Korobeynikov; Anna Gaponova; Ilya G Serebriiskii; Meghan C Kopp; Harvey H Hensley; Tamina N Seeger-Nukpezah; Stefan Somlo; David A Proia; Erica A Golemis
Journal:  FASEB J       Date:  2018-01-10       Impact factor: 5.191

Review 3.  Hypertension in autosomal dominant polycystic kidney disease.

Authors:  Arlene B Chapman; Konrad Stepniakowski; Frederic Rahbari-Oskoui
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

Review 4.  Nephrology, dialysis and transplantation.

Authors:  K Farrington; P Sweny
Journal:  Postgrad Med J       Date:  1993-07       Impact factor: 2.401

Review 5.  Imaging approaches to patients with polycystic kidney disease.

Authors:  Arlene B Chapman; Wenjing Wei
Journal:  Semin Nephrol       Date:  2011-05       Impact factor: 5.299

6.  The HALT polycystic kidney disease trials: design and implementation.

Authors:  Arlene B Chapman; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Kyongtae T Bae; J Philip Miller; Dana C Miskulin; Frederic Rahbari Oskoui; Amirali Masoumi; Marie C Hogan; Franz T Winklhofer; William Braun; Paul A Thompson; Catherine M Meyers; Cass Kelleher; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2010-01       Impact factor: 8.237

Review 7.  Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.

Authors:  Tevfik Ecder; Robert W Schrier
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

8.  Quinapril hydrochloride effects on renal function in patients with renal dysfunction and hypertension: a drug-withdrawal study.

Authors:  M A Miller; M Texter; A Gmerek; J Robbins; L Shurzinske; D Canter
Journal:  Cardiovasc Drugs Ther       Date:  1994-04       Impact factor: 3.727

9.  Developments in the management of autosomal dominant polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Mir Reza Bekheirnia; Robert W Schrier
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.